PMID- 19773226
OWN - NLM
STAT- MEDLINE
DCOM- 20110111
LR  - 20091216
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 30
IP  - 24
DP  - 2009 Dec
TI  - Intracoronary bone marrow cell transfer after myocardial infarction: 5-year 
      follow-up from the randomized-controlled BOOST trial.
PG  - 2978-84
LID - 10.1093/eurheartj/ehp374 [doi]
AB  - AIMS: We assessed whether a single intracoronary infusion of autologous bone 
      marrow cells (BMCs) can have a sustained impact on left ventricular ejection 
      fraction (LVEF) in patients after ST-elevation myocardial infarction (STEMI). In 
      the BOne marrOw transfer to enhance ST-elevation infarct regeneration (BOOST) 
      trial, 60 patients with STEMI and successful percutaneous coronary intervention 
      were randomized to a control and a cell therapy group. As previously reported, 
      BMC transfer led to an improvement of LVEF by 6.0% at 6 months (P = 0.003) and 
      2.8% at 18 months (P = 0.27). METHODS AND RESULTS: Left ventricular ejection 
      fraction and clinical status were re-assessed in all surviving patients after 61 
      +/- 11 months. Major adverse cardiac events occurred with similar frequency in 
      both groups. When compared with baseline, LVEF assessed by magnetic resonance 
      imaging at 61 months decreased by 3.3 +/- 9.5% in the control group and by 2.5 
      +/- 11.9% in the BMC group (P = 0.30). Patients with an infarct transmurality > 
      median appeared to benefit from BMC transfer throughout the 61-month study period 
      (P = 0.040). CONCLUSION: A single intracoronary application of BMCs does not 
      promote a sustained improvement of LVEF in STEMI patients with relatively 
      preserved systolic function. It is conceivable that a subgroup of patients with 
      more transmural infarcts may derive a sustained benefit from BMC therapy. 
      However, this needs to be tested prospectively in a randomized trial.
FAU - Meyer, Gerd P
AU  - Meyer GP
AD  - Department of Cardiology and Angiology, Hannover Medical School, 
      Carl-Neuberg-Str. 1, 30625 Hannover, Germany. meyer.gerdp@mh-hannover.de
FAU - Wollert, Kai C
AU  - Wollert KC
FAU - Lotz, Joachim
AU  - Lotz J
FAU - Pirr, Jens
AU  - Pirr J
FAU - Rager, Ulrike
AU  - Rager U
FAU - Lippolt, Peter
AU  - Lippolt P
FAU - Hahn, Andreas
AU  - Hahn A
FAU - Fichtner, Stephanie
AU  - Fichtner S
FAU - Schaefer, Arnd
AU  - Schaefer A
FAU - Arseniev, Lubomir
AU  - Arseniev L
FAU - Ganser, Arnold
AU  - Ganser A
FAU - Drexler, Helmut
AU  - Drexler H
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
SB  - IM
MH  - Adult
MH  - Aged
MH  - Bone Marrow Transplantation/*methods
MH  - Follow-Up Studies
MH  - Humans
MH  - Magnetic Resonance Angiography
MH  - Middle Aged
MH  - Myocardial Infarction/physiopathology/*therapy
MH  - Stroke Volume/physiology
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Ventricular Dysfunction, Left/etiology/therapy
EDAT- 2009/09/24 06:00
MHDA- 2011/01/12 06:00
CRDT- 2009/09/24 06:00
PHST- 2009/09/24 06:00 [entrez]
PHST- 2009/09/24 06:00 [pubmed]
PHST- 2011/01/12 06:00 [medline]
AID - ehp374 [pii]
AID - 10.1093/eurheartj/ehp374 [doi]
PST - ppublish
SO  - Eur Heart J. 2009 Dec;30(24):2978-84. doi: 10.1093/eurheartj/ehp374.